Neal Walker - Feb 1, 2025 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
INTERIM CEO, Director
Signature
/s/ Matthew Rothman, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Feb 1, 2025
Transactions value $
-$8,826
Form type
4
Date filed
2/4/2025, 04:15 PM
Previous filing
Jan 3, 2025
Next filing
Mar 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +9.47K +0.65% 1.46M Feb 1, 2025 Direct F1
transaction ACRS Common Stock Tax liability -$8.83K -3.56K -0.24% $2.48 1.46M Feb 1, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -9.47K -25% $0.00 28.4K Feb 1, 2025 Common Stock 9.47K Direct F1, F3
transaction ACRS Restricted Stock Units Award $0 +254K $0.00 254K Feb 3, 2025 Common Stock 254K Direct F1, F4
transaction ACRS Employee Stock Option (Right to Buy) Award $0 +889K $0.00 889K Feb 3, 2025 Common Stock 889K $2.40 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2 The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3 The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO.
F4 The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F5 Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.